Eli Lilly said it will pay $200 million cash to gene-editing firm Beam Therapeutics for Beam’s stake in Verve Therapeutics, another gene-editing company focused on treatments for heart disease.
Comments
\(°ロ\)
There's nothing here…
Eli Lilly said it will pay $200 million cash to gene-editing firm Beam Therapeutics for Beam’s stake in Verve Therapeutics, another gene-editing company focused on treatments for heart disease.